Peptide library / IGF-1 LR3

IGF-1 LR3

IGF-1 LR3 is an engineered insulin-like growth factor 1 analog with sequence changes that distinguish it from native IGF-1 and prescription mecasermin.

Peptide & blend guide

The short version

Why people discuss it
Discussed for muscle growth and exercise recovery. Community interest does not establish benefit or a suitable treatment.
What it is
IGF-1 LR3 is an engineered insulin-like growth factor 1 analog with sequence changes that distinguish it from native IGF-1 and prescription mecasermin.
Biggest caution
Results for native IGF-1 or mecasermin cannot supply efficacy, dosing or safety conclusions for LR3. Potent growth-factor activity and unverified product identity make extrapolation especially unreliable.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

Subcutaneous or intramuscular injection

Community reference · Not clinical guidance
Amount
40–80 mcg
Frequency
Once daily
Duration / phase
4–6 weeks

Community pattern without healthy-human dose-finding Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library